FUSCC Refractory TNBC Platform Study (FUTURE2.0)

Abroad (travel likely)RecruitingPHASE2

Conditions

Triple-negative Breast Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Fudan University Shanghai Cancer Center, Shanghai, China
Contact: Study coordinator (Zhimin Shao, M.D.) · zhimingshao@yahoo.com
Contact: Study coordinator (Yin Liu, M.D.) · liuyinfudan@163.com

Study leads

Zhimin Shao, M.D.
Principal Investigator
Fudan University

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK

Triple-negative Breast Cancer · TNBC - Triple-Negative Breast Cancer

Abroad (travel likely)RecruitingPHASE2

Aarau, Switzerland · Basel, Switzerland

A Study of MR001 in Patients With Locally Recurrent or Metastatic Advanced Triple-Negative Breast Cancer (TNBC)

Triple-Negative Breast Cancer (TNBC)

Abroad (travel likely)RecruitingPHASE1, PHASE2

Beijing, China

Neoadjuvant Chemotherapy Combined With Sintilimab and Bevacizumab for TNBC (NEOTORCH-BREAST07)

TNBC - Triple-Negative Breast Cancer

Abroad (travel likely)RecruitingPHASE2

Hefei, China · Shanghai, China

Tislelizumab Combined with Nab-Paclitaxel for First-Line Treatment of Advanced Triple-Negative Breast Cancer with Bone Metastasis，an Exploratory, Single-Arm, Multicenter Phase II Clinical Study

Triple-negative Breast Cancer · Bone Metastases

Abroad (travel likely)RecruitingPHASE2

Hangzhou, China